If this message does not appear correctly, click this link

Corporate News

ACT Genomics collaborates with AstraZeneca Singapore on BRCA testing

ACT Genomics is honoured to collaborate with AstraZeneca Singapore for both somatic and germline genetic testing of BRCA in patients with ovarian cancer, using the advanced next generation sequencing (NGS) technology. International guidelines such as those from ESMO, ASCO and NCCN recommend BRCA testing, which will provide patients and doctors with important information on disease prognosis and may improve treatment decisions.

With the advancements in precision medicine, patient care can now be managed better. ACT Genomics is proud to be part of patients’ journey and together we “Turn Genomics into Action."

Speeches & Conferences

03/20 Hong Kong Precision Oncology Symposium to discuss genetic testing and protection from genetic discrimination

With advances in technologies of genetic testing, increasing subsets of cancer patients are found to harbor germline mutations. While having knowledge of the germline mutations allows better risk management, it may also subject the patient and family members to discrimination.

A precision oncology symposium is being held in Hong Kong on March 20th to discuss genetic testing and its ethical aspects. Dr. Shu-Jen Chen, Chief Scientific Officer of ACT Genomics, will start off the symposium by explaining the current technologies of genetic testing and hereditary genes. Following Dr. Chen’s talk, other renowned experts in the field will discuss the oncological management of hereditary cancers, the current situations in Hong Kong, and the possible ways to protect individuals undergoing genetic testing from discrimination.

02/28 ACT Genomics invited to speak at Shanghai immunotherapy conference

Immunotherapy, although often considered the most promising cancer therapy in decades, currently still faces major challenges in identifying patients most likely to respond. With the help of comprehensive genomic profiling, finding appropriate biomarkers for immunotherapy is becoming a key driving force in the advancement of immunotherapy.

Tigermed and Teddy Clinical Research Laboratory (Shanghai) are hosting a conference in Shanghai on February 28th to discuss the role precision medicine plays in immunotherapy. ACT Genomics’ Chief Scientific Officer, Dr. Shu-Jen Chen, is invited to share ACTG’s experiences on evaluating immunotherapy with genomic profiling in Asia Pacific. Dr. Shun Lu, professor of Shanghai Chest Hospital and member of ASCO International Affairs Committee, is also invited to share the latest development in predictive biomarkers and lung cancer management.

02/23-25 ACT Genomics attends 13th International Conference of Asian Clinical Oncology Society

ACT Genomics will be attending the 13th International Conference of the Asian Clinical Oncology Society (ACOS). ACOS, held every two years in Asia Pacific, will take place in Chiang Mai, Thailand this year on February 23-25, with over 500 professionals attending. ACOS is devoted to the care of cancer patients and the development of scientific knowledge by having the scientific exchanges and sharing the best and most up-to-date information with Asian countries. More details about ACOS 2018: http://acos2018.com/

Image title

02/07-08 Join us at the "Future of Personalized and Precision Medicine" Conference in Singapore

What will our future be like in the era of precision medicine? Dr. Allen Lai, ACT Genomics’ senior VP, is honored to be a keynote speaker at the “Future of Personalized and Precision Medicine” conference in Singapore to speak on the topic of “The Reality and Challenges of Precision Medicine.” Dr. Lai will discuss the complexities and clinical implementation of cancer genomics in Asia.

ACT Genomics’ Medical Liaison, Dr. Poon Song Ling, will join a few other panelists to discuss “Aiming High for Precision Medicine – a World without Disease?” Dr. Poon explores how precision medicine is transforming current healthcare model from hospital-centric to patient-centric and the advancement of precision medicine from novelty to necessity. More info on the conference: http://claridenglobal.com/conference/precisionmedicine-sg-2018/

Image title

01/25 ACT Genomics shares precision oncology experiences at Penang cancer hospital

ACT Genomics is honoured to share precision oncology experiences at one of the major cancer hospitals in Penang, Malaysia in a talk titled “Reality or Fantasy: Using Next Generation Sequencing to Timely Match the Right Patients with the Right Treatment in Cancer Care.”

Image title

Talazoparib may show clinical activity in BRCA-mutated breast cancer

Abstract: Based on the results of a phase III EMBRACA trial, talazoparib exhibited response in advanced BRCA-mutated breast cancer. See more...

Image title

NSD genetic alterations show good prognostic value for laryngeal cancer

Abstract: Based on the combined data of genetic alterations, gene expression and epigenetics from 256 SCCHN (squamous cell carcinoma of head and neck) patients, NSD1 and NSD2 mutations show better prognosis in laryngeal subgroups. See more...

Image title

Aberrant clonal expansions often interfere with germ-line TP53 genetic testing result

Abstract: Blood and saliva are often used for the germ-line genetic testing of TP53. However, aberrant clonal expansion is an interference for germ-line test result, leading to an increased false positive rate. If the test detected more than two mutations, DNA from another source should be used to confirm the germ-line mutation. See more ...

Image title

Using genetic information to create a new cancer model for DCIS progression to IDC breast cancer

Abstract: The cancer evolution is poorly understood in DCIS and IDC breast cancer. A new study used genomics information to construct a new model for cancer evolution. The results reveal future directions to assess the risk of DCIS patients progressing to IDC. See more...

Image title

A new kinase inhibitor shows the promising results in advanced GIST

Abstract: In a phase I study, heavily pretreated patients with gastrointestinal stromal tumors (GIST) were treated with a new kinase inhibitor, DCC-2618. The updated data revealed that the DCC-2618 had a promising disease control rate and a reduced mutation allele frequency in plasma cell-free DNA. See more...

  To unsubscribe, please enter your E-Mail :